Heart failure drug shows unexpected kidney protection in major trial

A diabetes medication used in heart failure patients provided significant kidney protection, according to data from a major cardiovascular trial. The finding could reshape treatment protocols for millions of patients with both conditions and potentially reduce costly kidney complications that drive healthcare spending.

Originaltitel: Effects of Ertugliflozin on Kidney Outcomes in Patients With Heart Failure at Baseline in the Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes (VERTIS CV) Trial